Telix Pharmaceuticals Ltd., of Melbourne, Australia, said it will work with the German Cancer Research Center (Deutsches Krebsforschungszentrum) on image-guided prostate cancer surgery using a radiotracer based on 68Ga-PSMA-11, currently under development by Telix as TLX591-CDx and marketed as Illumet in the U.S.